43 related articles for article (PubMed ID: 29274493)
1. Novel Saccharomyces cerevisiae screen identifies WR99210 analogues that inhibit Mycobacterium tuberculosis dihydrofolate reductase.
Gerum AB; Ulmer JE; Jacobus DP; Jensen NP; Sherman DR; Sibley CH
Antimicrob Agents Chemother; 2002 Nov; 46(11):3362-9. PubMed ID: 12384337
[TBL] [Abstract][Full Text] [Related]
2. Synthesis, molecular docking study and biological evaluation of new pyrrole scaffolds as potential antitubercular agents for dual targeting of enoyl ACP reductase and dihydrofolate reductase.
Mahnashi MH; Avunoori S; Gopi S; Shaikh IA; Saif A; Bantun F; Faidah HS; Alhadi AA; Alshehri JH; Alharbi AA; S R PK; Joshi SD
PLoS One; 2024; 19(5):e0303173. PubMed ID: 38739587
[TBL] [Abstract][Full Text] [Related]
3. Exploring the potential and identifying
Gurushankar K; Rimac H; Nadezhda P; Grishina M
J Biomol Struct Dyn; 2023; 41(23):13963-13976. PubMed ID: 36762693
[TBL] [Abstract][Full Text] [Related]
4. Host dihydrofolate reductase (DHFR)-directed cycloguanil analogues endowed with activity against influenza virus and respiratory syncytial virus.
Tonelli M; Naesens L; Gazzarrini S; Santucci M; Cichero E; Tasso B; Moroni A; Costi MP; Loddo R
Eur J Med Chem; 2017 Jul; 135():467-478. PubMed ID: 28477572
[TBL] [Abstract][Full Text] [Related]
5. Exploration and Biological Evaluation of 1,3-Diamino-7
Zhu Z; Chen C; Zhang J; Lai F; Feng J; Wu G; Xia J; Zhang W; Han Z; Zhang C; Yang Q; Wang Y; Liu B; Li T; Wu S
J Med Chem; 2023 Oct; 66(20):13946-13967. PubMed ID: 37698518
[TBL] [Abstract][Full Text] [Related]
6. Cymoxanil disrupts RNA synthesis through inhibiting the activity of dihydrofolate reductase.
Kazmirchuk TDD; Burnside DJ; Wang J; Jagadeesan SK; Al-Gafari M; Silva E; Potter T; Bradbury-Jost C; Ramessur NB; Ellis B; Takallou S; Hajikarimlou M; Moteshareie H; Said KB; Samanfar B; Fletcher E; Golshani A
Sci Rep; 2024 May; 14(1):11695. PubMed ID: 38778133
[TBL] [Abstract][Full Text] [Related]
7. Fragment-Merging Strategies with Known Pyrimidine Scaffolds Targeting Dihydrofolate Reductase from Mycobacterium tuberculosis.
Kirkman T; Fun Tan S; Chavez-Pacheco SM; Hammer A; Abell C; Tosin M; Coyne AG; Dias MVB
ChemMedChem; 2023 Aug; 18(15):e202300240. PubMed ID: 37195570
[TBL] [Abstract][Full Text] [Related]
8. Identification of Novel Coumestan Derivatives as Polyketide Synthase 13 Inhibitors against Mycobacterium tuberculosis.
Zhang W; Lun S; Wang SH; Jiang XW; Yang F; Tang J; Manson AL; Earl AM; Gunosewoyo H; Bishai WR; Yu LF
J Med Chem; 2018 Feb; 61(3):791-803. PubMed ID: 29328655
[TBL] [Abstract][Full Text] [Related]
9. Pharmacological validation of dihydrofolate reductase as a drug target in
Aragaw WW; Negatu DA; Bungard CJ; Dartois VA; Marrouni AE; Nickbarg EB; Olsen DB; Warrass R; Dick T
Antimicrob Agents Chemother; 2024 Jan; 68(1):e0071723. PubMed ID: 38018963
[TBL] [Abstract][Full Text] [Related]
10. The implication of Mycobacterium tuberculosis-mediated metabolism of targeted xenobiotics.
Singh V; Dziwornu GA; Chibale K
Nat Rev Chem; 2023 May; 7(5):340-354. PubMed ID: 37117810
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and Characterization of Phenylalanine Amides Active against
Lang M; Ganapathy US; Mann L; Abdelaziz R; Seidel RW; Goddard R; Sequenzia I; Hoenke S; Schulze P; Aragaw WW; Csuk R; Dick T; Richter A
J Med Chem; 2023 Apr; 66(7):5079-5098. PubMed ID: 37001025
[No Abstract] [Full Text] [Related]
12. Potency boost of a
Aragaw WW; Lee BM; Yang X; Zimmerman MD; Gengenbacher M; Dartois V; Chui WK; Jackson CJ; Dick T
Proc Natl Acad Sci U S A; 2021 Jun; 118(25):. PubMed ID: 34161270
[TBL] [Abstract][Full Text] [Related]
13. Chemical Classes Presenting Novel Antituberculosis Agents Currently in Different Phases of Drug Development: A 2010-2020 Review.
Angula KT; Legoabe LJ; Beteck RM
Pharmaceuticals (Basel); 2021 May; 14(5):. PubMed ID: 34068171
[TBL] [Abstract][Full Text] [Related]
14. Discovery of Oxazol-2-amine Derivatives as Potent Novel FLT3 Inhibitors.
Kim HJ; Ryu H; Song JY; Hwang SG; Jalde SS; Choi HK; Ahn J
Molecules; 2020 Nov; 25(21):. PubMed ID: 33167505
[TBL] [Abstract][Full Text] [Related]
15. Potential anti-TB investigational compounds and drugs with repurposing potential in TB therapy: a conspectus.
Adeniji AA; Knoll KE; Loots DT
Appl Microbiol Biotechnol; 2020 Jul; 104(13):5633-5662. PubMed ID: 32372202
[TBL] [Abstract][Full Text] [Related]
16. 1,2,3-Triazole-containing hybrids as leads in medicinal chemistry: A recent overview.
Bozorov K; Zhao J; Aisa HA
Bioorg Med Chem; 2019 Aug; 27(16):3511-3531. PubMed ID: 31300317
[TBL] [Abstract][Full Text] [Related]
17. 1,3,5-triazaspiro[5.5]undeca-2,4-dienes as selective Mycobacterium tuberculosis dihydrofolate reductase inhibitors with potent whole cell activity.
Yang X; Wedajo W; Yamada Y; Dahlroth SL; Neo JJ; Dick T; Chui WK
Eur J Med Chem; 2018 Jan; 144():262-276. PubMed ID: 29274493
[TBL] [Abstract][Full Text] [Related]
18. Antifolate and antiproliferative activity of 6,8,10-triazaspiro[4.5]deca-6,8-dienes and 1,3,5-triazaspiro[5.5]undeca-1,3-dienes.
Ma X; Chui WK
Bioorg Med Chem; 2010 Jan; 18(2):737-43. PubMed ID: 20036565
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
